Express News | Spyre Therapeutics: Spy002 Remains on Track to Begin First-in-Human Studies in H2 of 2024
Express News | Spyre to Present Interim Spy001 Data by Year-End 2024
Express News | Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of Spy001, Its Novel Half-Life Extended Anti-Α4Β7 Antibody, for the Treatment of Inflammatory Bowel Disease
Spyre Therapeutics Down Nearly 20%, on Pace for Largest Percent Decrease Since June 2023 -- Data Talk
Spyre Therapeutics, Inc (SYRE) is currently at $25.26, down $6.25 or 19.83% --Would be lowest close since Feb. 27, 2024, when it closed at $24.91 --Onpace for largest percent decrease since June 21,
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
LifeSci Capital analyst Sam Slutsky maintains $Spyre Therapeutics(SYRE.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 47.4%
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...
Spyre Therapeutics Announces Updated Share Structure
Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...
On May 14, 2024, Paragon Therapeutics Announced A License Agreement Granting Spyre Therapeutics An Exclusive License To Certain Antibodies And Products Targeting Α4SS7 Integrin And Tl1A, Paragon Will Up To $22M In Milestone Payments-8K
Paragon will provide the Company with an exclusive license to its patents covering the related antibody, the method of use and its method of manufacture.Paragon will not conduct any new campaigns that
Spyre Therapeutics Expands Portfolio and Strengthens Leadership
Express News | Spyre Therapeutics Appoints Accomplished Biopharma Leader DR. Sandra Milligan to Its Board of Directors
Positive Outlook on Spyre Therapeutics' IBD Pipeline and Financial Stability
Spyre Therapeutics Is Maintained at Overweight by Wells Fargo
Spyre Therapeutics Is Maintained at Overweight by Wells Fargo
Express News | Spyre Therapeutics, Inc. : Wells Fargo Raises Target Price to $40 From $35
Buy Rating Affirmed: Spyre Therapeutics' Promising Pipeline and Expert Team Drive Positive Outlook
Spyre Therapeutics Is Maintained at Buy by BTIG
Spyre Therapeutics Is Maintained at Buy by BTIG
Express News | BTIG Maintains Buy on Spyre Therapeutics, Raises Price Target to $40
Spyre Therapeutics: Strong Buy Recommendation on Robust Pipeline and Financial Stability
Express News | Spyre Therapeutics Inc : Btig Raises Target Price to $40 From $32
Express News | Spyre Therapeutics Q1 2024 GAAP EPS $(1.20) Misses $(1.17) Estimate
No Data